The iCAN Flagship Project is an extraordinary biobank study, globally unique in its scale and scope, that integrates deep molecular profiling data from tumors with comprehensive and dynamic longitudinal health data, exclusively accessible in Finland. Data analysis is enabled on the unique iCAN Discovery Platform.
The project aims to profile 10,000 patient samples across tumor types (pan-cancer). The study already involves in excess of 2500 participants and ongoing studies cover a wide range of cancers, including colorectal, gastric, pancreatic, breast, lung, ovarian, renal, prostate, bladder, melanoma, pediatric solid cancers, myeloid leukemias, lymphomas, and multiple myeloma.
iCAN Flagship Project is funded and governed as a public-private consortium and provides an excellent environment for exploratory investigations and fostering collaboration and innovation within the project.